Clinical Trial

The SAFE Prospective Registry

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 7, 2023 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
Secretoneurin (SN) is a neuropeptide from the chromogranin family that influences intracellular calcium handling. SN suppresses calcium leakage from the sarcoplasmic reticulum through the ryanodine receptor. SN is a novel biomarker that has shown the potential to predict adverse arrhythmic events.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-03-20.
Status change: Not Yet Recruiting → Recruiting 2023-09-06
Trial Details
NCT Number NCT05794464
Lead Sponsor University Hospital Ostrava
Conditions Atrial Fibrillation, Paroxysmal or Persistent
Enrollment 60 participants
Start Date 2023-05-01
Primary Completion 2026-05 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2023-09-07